DAANCE FOR CHEMOTHERAPY-INDUCED NEUROPATHY
Part of paid clinical trials in New Haven, Connecticut.
- Sponsor
- Ohio State University Comprehensive Cancer Center
- Study ID
- NCT06749210
- Phase
- PHASE2
- Status
- Recruiting
Conditions
- Cancer of the Breast
- Chemotherapy-induced Neuropathy
Eligibility Criteria
- Sex
- ALL
- Age
- 40 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Tango — BEHAVIORALThe intervention being studied is a 16 session intervention (2x4-week modules), delivered over an 8-week period by community-based individuals with expertise in dance and patient care and certified in Adapted Tango or AdapTango dance instruction. Steps available to teach, including order and cues to teach them, are detailed in Hackney's AdapTango manual. All steps are based on the Argentine Tango steps that emerged within working class community centers in Buenos Aires, Argentina (milongas) in the late 1800s and have been adapted by the investigators for use as medical exercise among people with mobility deficits. Of note, Argentine Tango is distinct from, and the precursor for, the American Tango style of competitive ballroom dance: where American Tango highlights showmanship and complicated footwork, Argentine Tango prioritizes connection between partners and musicality within a basic walk motion.
Study Details
Up to 80% of breast cancer survivors experience chemotherapy-induced neuropathy that impairs quality of life and increases fall risk long into survivorship, yet treatment options for neuropathy remain limited. The successful treatment will target neurophysiologic mechanisms for restoring function while addressing patient-reported symptoms and participation in treatment. Toward this end, the investigators propose to study a noninvasive, social sensorimotor intervention - Adapted Argentine Tango - which targets motor control restoration, symptom alleviation, and treatment participation in concert.
Key Dates
- Start date
- Feb 19, 2025
- Status verified
- Jul 2025
- Primary completion
- Aug 15, 2029
- Completion
- Aug 15, 2029
Study Design
- Enrollment
- 140 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- CROSSOVER
- Primary purpose
- SUPPORTIVE_CARE
Arms
- No Intervention: Control4 weeks of usual care followed by optional 1-way crossover to 8 weeks of Intervention (partnered, adapted tango dance)
- Experimental: Experimental8 weeks of intervention (partnered, adapted tango dance)
Primary Outcome Measure
Patient-Reported Outcome (PRO) - CIN sensation [ Time Frame: 4 weeks ]
Central Contacts
- Lise Worthen-Chaudhari, PhD, MFA, CMES(1) + 614-293-6281
Locations (2)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Yale University | New Haven | Connecticut | 06520 | Maryam Lustberg, MD, MPH Maryam Lustberg, MD, MPH (PRINCIPAL_INVESTIGATOR) |
| The Ohio State University | Columbus | Ohio | 43220 | Lise Worthen-Chaudhari, PhD, MFA, CMES (PRINCIPAL_INVESTIGATOR) |
Find similar trials in New Haven, CT
Related Studies
- Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast CancerPHASE2 · Recruiting · Proton Collaborative Group · Scottsdale, Arizona
- Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence ScorePHASE2 · Recruiting · Washington University School of Medicine · St Louis, Missouri
- Treatment Monitoring of Patients Receiving CDK 4/6 Inhibitors for Hormone Receptor (HR) Positive, HER2 Negative Metastatic Breast Cancer (MBC) With or Without the Addition of DiviTum® Serum Thymidine Kinase 1 (TK1) Activity TestingRecruiting · Washington University School of Medicine · St Louis, Missouri
- NeoTAILOR: ABiomarker-directed Approach to Guide Neoadjuvant Therapy for Patients With Stage II/III ER-positive, HER2-negative Breast CancerPHASE2 · Recruiting · Washington University School of Medicine · St Louis, Missouri